TSLP
Thymic stromal lymphopoietin
As of the edition of 20 October 2026, TSLP (thymic stromal lymphopoietin, UniProt Q969D9) has 8 drugs tested at it and 9 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q969D9
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 5
- Disease areas
- Immune system; Lungs and airways; Skin and connective tissue; Ear, nose and throat; Inherited and neonatal; Blood and lymph; Heart and blood vessels; Infections
- Registered trials of its drugs
- 76
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 4 |
| Stopped | 1 |
| Status not established | 2 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tezepelumab | Marketed | Phase 4 | Ends 2033 |
| GSK5784283 | Active | Phase 3 | none listed |
| IBI3002 | Active | Phase 2 | none listed |
| CSJ117 | Stopped | Phase 2 | none listed |
| CDX-622 | Active | Phase 1 | none listed |
| TAVO101 | Status not established | Phase 2 | none listed |
| WIN378 | Active | Phase 2 | none listed |
| SAR443765 | Status not established | Phase 1 | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 4 |
| Undetermined | 3 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Novartis | Route A |
The other 7 companies at TSLP
In the product9 companies in all; 7 are not named here, and no score is.
See the 9 companies at TSLP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.